Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study

Objective To investigate tolerability and efficacy of low molecular weight (LMW) hepa rin therapy in patients with severe Raynaud's phenomenon. Methods A prospective parallel group study comparing patients receiving regular sub cutaneous LMW heparin (n = 16) with a matched control group (n = 14). End-p oints were change in Raynaud's attack severity, non-invasive vascular studi es or serum levels of circulating soluble adhesion molecules. Results There was overall improvement in Raynaud's attack severity during heparin t herapy (p = 0.0002). This was observed after 4 weeks, and was maximal by 20 weeks. Mean finger blood flow recovery time improved, and serum levels of circulating ICAM-1, VCAM-1 and E-selectin were lower at completion of hepar in therapy, but changes did not reach statistical significance. Conclusion This study suggests that LMW heparin therapy is well tolerated, and potenti ally beneficial, in patients with severe Raynaud's phenomenon, and justifie s further evaluation.